- Home
- JANX vs MTX Comparison
JANX vs MTX Comparison
Compare JANX & MTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- MTX
- Stock Information
- Founded
- JANX 2017
- MTX 1968
- Country
- JANX United States
- MTX United States
- Employees
- JANX N/A
- MTX N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- MTX Major Chemicals
- Sector
- JANX Health Care
- MTX Industrials
- Exchange
- JANX Nasdaq
- MTX Nasdaq
- Market Cap
- JANX 1.6B
- MTX N/A
- IPO Year
- JANX 2021
- MTX 1992
- Fundamental
- Price
- JANX $26.37
- MTX $55.20
- Analyst Decision
- JANX Strong Buy
- MTX Strong Buy
- Analyst Count
- JANX 7
- MTX 2
- Target Price
- JANX $94.29
- MTX $80.00
- AVG Volume (30 Days)
- JANX 974.6K
- MTX 286.0K
- Earning Date
- JANX 05-20-2025
- MTX 04-24-2025
- Dividend Yield
- JANX N/A
- MTX 0.80%
- EPS Growth
- JANX N/A
- MTX N/A
- EPS
- JANX N/A
- MTX N/A
- Revenue
- JANX $10,588,000.00
- MTX $2,075,800,000.00
- Revenue This Year
- JANX N/A
- MTX $2.19
- Revenue Next Year
- JANX $250.58
- MTX $4.80
- P/E Ratio
- JANX N/A
- MTX N/A
- Revenue Growth
- JANX 30.99
- MTX N/A
- 52 Week Low
- JANX $22.52
- MTX $49.54
- 52 Week High
- JANX $71.71
- MTX $90.30
- Technical
- Relative Strength Index (RSI)
- JANX 39.10
- MTX 46.66
- Support Level
- JANX $31.34
- MTX $51.87
- Resistance Level
- JANX $33.97
- MTX $53.96
- Average True Range (ATR)
- JANX 1.94
- MTX 2.22
- MACD
- JANX -0.52
- MTX 0.40
- Stochastic Oscillator
- JANX 22.76
- MTX 57.99
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.